Drug Gene Delivery Devices Market Size and Share - Growth Analysis Report and Forecast Trends 2026-2030

The Drug and Gene Delivery Devices market sits at the intersection of advanced therapeutics and enabling hardware, supplying the physical tools that allow biologics, nucleic acids, and modified cells to reach their intended biological targets. In 2025 the global market is valued at roughly $0.98 billion, with analysts projecting a compound annual growth rate near 9.78% over the forecast period. Because cell and gene therapies are difficult to administer through conventional routes, dedicated devices, from electroporators and viral vector production systems to lipid nanoparticle injectors, have become a critical bottleneck and a high-value niche within the much larger pharmaceutical delivery sector.

• •Global market size in 2025: approximately USD 0.98 billion
• •Projected CAGR: around 9.78% over the forecast horizon
• •The market is a high-growth sub-segment of the broader pharmaceutical drug delivery industry, which itself exceeds USD 2 trillion

The principal engine of growth is the rising number of approved and clinical-stage cell and gene therapies, each of which depends on purpose-built delivery hardware to reach patients safely. Chronic and rare disease prevalence, combined with growing acceptance of one-time curative treatments, is pushing biopharmaceutical companies to scale up manufacturing and delivery infrastructure. Technological progress in non-viral methods, such as lipid nanoparticles and electroporation, is also lowering barriers to entry and enabling repeat dosing, which broadens the addressable patient population.

• •Surge in FDA and EMA approvals of gene and cell therapies creates sustained device demand
• •Advances in lipid nanoparticle and electroporation technologies enable safer, scalable delivery
• •Growing investment in personalized medicine expands the clinical use cases for gene-based treatments

The market can be segmented by delivery technology, including viral vectors, electroporation, and non-viral carriers such as lipid nanoparticles, and by therapeutic application spanning oncology, rare genetic disorders, and infectious disease. North America currently leads due to its concentration of gene therapy developers and supportive regulatory frameworks, while Asia-Pacific is emerging as the fastest-growing region as countries such as China, Japan, and South Korea expand their cell and gene therapy pipelines. Europe maintains a strong position through its advanced biomedical research ecosystem and centralized reimbursement pathways.

• •North America holds the largest revenue share, driven by U.S.-based biotech activity
• •Asia-Pacific is the fastest-growing region, supported by expanding clinical pipelines and manufacturing capacity
• •Oncology and rare disease applications account for the majority of device utilization

What are the recent trends and outlook?

The most prominent trend is the shift toward in vivo delivery systems, particularly lipid nanoparticle platforms popularized by mRNA vaccines, which promise scalable and non-immunogenic alternatives to viral vectors. Automation of cell processing and closed-system manufacturing is also gaining traction, helping reduce contamination risk and labor costs in clinical production. Looking ahead, the market is expected to nearly double by the early 2030s, supported by broader therapeutic indications, regulatory expansion into new geographies, and continued capital inflows into advanced therapy developers.

• •In vivo lipid nanoparticle delivery is displacing some viral vector applications
• •Automation and closed-system devices are improving manufacturing throughput
• •The market is projected to roughly double by the early 2030s, maintaining growth above 9% annually